A 28-year-old woman with generalized tonic-clonic seizures has been seizure-free for 2 years on phenytoin monotherapy. She now presents to the outpatient clinic planning pregnancy. Her seizure control is excellent, but she is concerned about teratogenicity. On examination, she has mild gingival hyperplasia and coarse facial features. What is the most appropriate next step in her antiepileptic management?

Explanation

## Clinical Context This patient is a woman of childbearing age on phenytoin, a first-generation antiepileptic with significant teratogenic potential and chronic adverse effects (gingival hyperplasia, coarse facies, hirsutism). ## Key Considerations for Pregnancy Planning **Key Point:** Phenytoin is associated with fetal hydantoin syndrome (cleft palate, cardiac defects, growth restriction, developmental delay) and carries a 2–3% risk of major congenital anomalies—higher than many newer agents. **High-Yield:** Newer antiepileptics (lamotrigine, levetiracetam, oxcarbazepine) have lower teratogenic risk profiles and should be preferred in women of childbearing potential, especially when seizure control permits a planned switch. **Clinical Pearl:** The ideal time to optimize antiepileptic therapy is *before* conception, when medication changes can be made without the urgency of an unplanned pregnancy and with time to establish seizure control on the new regimen. ## Management Algorithm ```mermaid flowchart TD A[Woman of childbearing age on phenytoin]:::outcome --> B{Planning pregnancy?}:::decision B -->|Yes| C{Seizure control adequate?}:::decision C -->|Yes| D[Switch to lower-teratogenic agent]:::action C -->|No| E[Optimize current therapy first]:::action D --> F[Preferred: lamotrigine or levetiracetam]:::action F --> G[Allow 3 months stabilization pre-conception]:::action B -->|No| H[Continue current therapy]:::action ``` ## Comparison of Antiepileptics in Pregnancy | Agent | Teratogenic Risk | Fetal Syndrome | Recommendation | |-------|------------------|----------------|----------------| | Phenytoin | 2–3% major anomalies | Fetal hydantoin syndrome | Avoid if possible | | Valproate | 10–20% major anomalies | Developmental delay, spina bifida | Contraindicated | | Carbamazepine | 1–2% major anomalies | Rare carbamazepine syndrome | Acceptable alternative | | Lamotrigine | 0.5–1% major anomalies | No specific syndrome | Preferred choice | | Levetiracetam | <1% major anomalies | No specific syndrome | Preferred choice | **Key Point:** Lamotrigine and levetiracetam are considered the safest options for pregnancy and should be the target agents for this patient. ## Why Folic Acid Alone Is Insufficient Folic acid supplementation reduces the risk of neural tube defects but does NOT address the broader teratogenic effects of phenytoin (cardiac defects, cleft palate, growth restriction). Switching to a safer agent is the definitive approach. ## Timing and Counseling - Switch should occur **before conception** to allow 3 months for stabilization and seizure control assessment. - If seizure control is maintained on the new agent, the pregnancy can proceed with confidence. - Dose adjustments may be needed during pregnancy (especially lamotrigine, which undergoes increased glucuronidation). [cite:KD Tripathi 8e Ch 12]